Cortexin
Cortexin is a peptide, indexed here under Short peptide bioregulators.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Short peptide bioregulators |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Cortexin, as the name is used in research-peptide catalogues, is a polypeptide preparation from animal cerebral cortex rather than a defined molecule, so PubChem returned no compound record and the identity fields on this page are unsourced. The same name is also used for an unrelated neuron-specific 82-residue membrane protein reported in a 1993 Journal of Neurochemistry paper; that protein is not the subject of this page. A 2015 Zhurnal Nevrologii i Psikhiatrii review covers molecular mechanisms and targets of the preparation’s neuroprotective activity, and a 2021 PLoS One paper compares cortexin, cerebrolysin and actovegin in acute and chronic brain ischaemia in rats.
The clinical records are Russian-language multicentre studies in the same journal: a 2018 dose-dependent study in chronic cerebral ischaemia, a 2018 multicentre study of cognitive dysfunction in children, a 2018 comparison with memantine in cognitive impairment, a 2020 comparative study with cerebrolysin and actovegin on memory impairment and cerebral circulation, and a 2022 study in post-COVID syndrome. The Drugs@FDA register returned no application for the name.
[2, 3, 4, 5, 6, 7, 8, 9]Reported mechanism
A cortical polypeptide preparation rather than a single molecule; the retrieved 2015 review discusses neuroprotective targets and the 2021 rat study compares it with other neurotrophic preparations, with no single receptor named.
[3, 4]Stated in the titles of the cited 2015 Zhurnal Nevrologii i Psikhiatrii review and 2021 PLoS One paper.
Targets named in the cited records: neuroprotective signalling, target not established.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Cortexin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- cortexin polypeptide complex
- bovine cortex polypeptide preparation
Where this page sits
Research records
Cited research records for Cortexin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Cerebrolysin — Neuroactive peptides
- Pinealon — Short peptide bioregulators
- Cortagen — Short peptide bioregulators
Class page: Short peptide bioregulators. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Cortexin?
Cortexin, as the name is used in research-peptide catalogues, is a polypeptide preparation from animal cerebral cortex rather than a defined molecule, so PubChem returned no compound record and the identity fields on this page are unsourced. The same name is also used for an unrelated neuron-specific 82-residue membrane protein reported in a 1993 Journal of Neurochemistry paper; that protein is not the subject of this page.
Which class is Cortexin indexed under?
Cortexin is indexed under Short peptide bioregulators. This class groups the short synthetic peptides and tissue polypeptide extracts developed by the St Petersburg bioregulator programme, which research-peptide catalogues sell as a family.
What does the FDA application register show for Cortexin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cortexin
- Identification of cortexin: a novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex. Journal of neurochemistry (1993). pmid:8336151
- [Cortexin. Molecular mechanisms and targets of neuroprotective activity]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2015). pmid:26356623
- Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PloS one (2021). pmid:34260655
- [Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2018). pmid:30335070
- [Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2018). pmid:29652302
- [The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2018). pmid:29460902
- [Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2020). pmid:32929929
- [Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022). pmid:35175707
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.